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مسببات فرط بروالكتني الدم
حتليل اْسِتَعاِدي من مركز للرعاية الصحية من املستوى الثالث
اأزهر مالك، في�شل عزيز، �شامل ب�شيه، خالد الدهماين
abstract: Objectives: This study aimed to evaluate the aetiologies of hyperprolactinaemia in the United Arab 
Emirates (UAE). Methods: This retrospective study used laboratory databases to identify all patients who underwent 
evaluation for prolactin at Tawam Hospital, Al Ain, UAE, between 2009 and 2015. Of those 2,280 patients, all 
patients with low or normal prolactin (n = 1,315) were excluded. Subsequently, charts of the remaining patients (n 
= 965) with hyperprolactinaemia were reviewed and those with incomplete work-ups or insufficient documentation 
of the hyperprolactinaemia’s aetiology were excluded (n = 458). Results: A total of 507 patients were included in 
the study. The average age at prolactin evaluation was 36 ± 13.2 years and the majority (67.1%) of patients were 
female. The most common reasons for requesting prolactin were menstrual disorders (29.5%), infertility (18%), 
evaluation of sellar masses (14.3%), ruling out seizures (13.4 %) and monitoring while on psychiatric medications 
(8.7%). The most common causes of hyperprolactinaemia were prolactinoma (17%), transient hyperprolactinaemia 
(14.6%), drug-induced side effects (14.4%), polycystic ovarian syndrome (11.8%) and seizure disorder (7.7%). In 
females, common aetiologies were prolactinomas, transient and idiopathic hyperprolactinaemia, while sellar masses, 
seizures, chronic kidney disease and acute illnesses were common aetiologies of hyperprolactinaemia in males. 
The prolactin level varied between the different aetiologies and a level of >250 ng/mL was suggestive of macro- 
prolactinoma. Conclusion: A significant proportion of patients with hyperprolactinaemia have transient hyper- 
prolactinaemia. Before further investigations are carried out, prolactin level assessment should be repeated, esp- 
ecially in patients with mild hyperprolactinaemia.
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امللخ�ص: الهدف: هدفت هذه الدرا�شة اإىل تقييم م�شببات فرط بروالكتني الدم يف دولة االإمارات العربية املتحدة. الطريقة: ا�شتخدمت هذه 
ة قواعد البيانات املخربية لتحديد جميع املر�شى الذين خ�شعوا لتقييم بروالكتني الدم يف م�شت�شفى توام، العني، االإمارات  الدرا�شة اال�ْشِتَعاِديَّ
العربية املتحدة، بني عامي 2009-2015. من اجمايل 2,280 مري�س مت ا�شتبعاد املر�شى الذين لديهم م�شتوى بروالكتني منخف�س اأوطبيعي 
يف الدم ثم متت مراجعة �شجالت مر�شى فرط بروالكتني الدم املتبقني وعددهم 965 مري�شا والذين بدورهم ا�شتثني منهم 458 حالة ب�شبب 
حتاليل غري كاملة اأوعدم توثيق م�شبب فرط بروالكتني الدم. النتائج: �شملت الدرا�شة ما جمموعه 507 مري�شا. كان متو�شط اعمارهم عند تقييم 
بروالكتني الدم لديهم 36 ± 13.2 �شنة وكان غالبية املر�شى )%67.1( من االإناث ومن االأ�شباب االأكرث �شيوًعا لطلب الربوالكتني هي ا�شطرابات 
الدورة ال�شهرية )%29.5( والعقم )%18( وتقييم اأورام ال�رشج الرتكي )%14.3( وا�شتبعاد النوبات االأختالجية )%13.4( ومتابعة املر�شى اأثناء 
تناول اأدوية عالج االمرا�س النف�شية )%8.7(. كانت اأكرث اأ�شباب فرط بروالكتني الدم �شيوًعا هي الورم الرُبواَلْكتيِنّي )%17( وفرط بروالكتني 
الدم العابر )%14.6( وكاأحد االعرا�س اجلانبية الناجمة عن تناول االأدوية )%14.4( ومتالزمة تكي�س املباي�س )%11.8( وا�شطرابات النوبات 
االأختالجية )%7.7(. ومن امل�شببات ال�شائعة لدى االإناث هي الورم الرُبواَلْكتيِنّي وفرط بروالكتني الدم العابر واملجهول ال�شبب، يف حني اأن 
اأورام ال�رشج الرتكي واال�شطرابات االأختالجية واملر�س الكلوي املزمن واالأمرا�س احلادة كانت من امل�شببات ال�شائعة لفرط بروالكتني الدم 
عند الذكور. كان هناك تباين يف م�شتوى الربوالكتني ح�شب امل�شببات املختلفة وي�شري م�شتوى بروالكتني اكرث من 250 نانوغرام/مل اىل ورم 
بُرواَلْكتيِنّي كبري احلجم. اخلال�صة: هناك ن�شبة كبرية من مر�شى فرط بروالكتني الدم لديهم فرط بروالكتني دم عابرلذا ينبغي تكرار تقييم 
م�شتوى الربوالكتني قبل القيام باإجراء املزيد من االأ�شتق�شاءات وخا�شة يف املر�شى الذين لديهم فرط طفيف يف بروالكتني الدم.
الكلمات املفتاحية: فرط بروالكتني الدم؛ ورم بُرواَلْكتيِنّي؛ امل�شببات؛ علم االأوبئة؛ االإمارات العربية املتحدة.
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Advances in Knowledge
- A large proportion of patients with hyperprolactinaemia have a transient rise of prolactin that normalises spontaneously and requires 
no further evaluation. 
- A prolactin level of >250 ng/mL is suggestive of the presence of macroprolactinoma. 
Application to Patient Care
- To avoid unnecessary investigations, repeating prolactin level assessment is recommended in patients with mild hyperprolactinaemia. 
- Knowledge of prolactin levels may predict the aetiology of hyperprolactinaemia and narrow the differential diagnosis.
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Prolactin is an important hormone of the anterior pituitary gland with diverse effects on the body’s systems, especially in the repro- 
ductive system.1 Hyperprolactinaemia, defined as a 
prolactin level above the laboratory gender-specific 
normal range, is a common endocrine problem world- 
wide.2–4 It is more common in females and its prev- 
alence has increased over the last two decades.5 Hyper- 
prolactinaemia can cause menstrual disorders, gynae- 
comastia, decreased libido, impotence and infertility.1
Hyperprolactinaemia can be caused by physio- 
logical changes, pathological conditions, medications, 
macroprolactin excess or can be idiopathic.6,7 The main 
physiological causes are pregnancy, lactation and stress, 
while common pathological causes include prolactinomas, 
other sellar masses, polycystic ovarian syndrome (PCOS), 
chronic kidney disease (CKD) and hypothyroidism.6,7 
Antipsychotics, antidepressants and anti-emetics are 
among the most common medications that cause hyper- 
prolactinaemia.8 Macroprolactin is a large molecule of 
prolactin mostly attached to immunoglobulins and can 
result in hyperprolactinaemia due to reduced renal 
clearance.9 
Knowledge of prevalence and causes of hyper- 
prolactinaemia primarily stem from studies conducted 
outside the Middle East and North Africa (MENA) 
region.3–5,10 To the best of the authors’ knowledge, no 
data have been published on the aetiology of hyperprolac- 
tinaemia in the United Arab Emirates (UAE). Therefore, 
this study aimed to determine the causes of hyperpro- 
lactinaemia in a large referral centre in the UAE. 
Methods
This retrospective study was conducted at Tawam 
Hospital, Al Ain, UAE, between 2009 and 2015. Tawam 
Hospital is the largest tertiary healthcare centre in Al 
Ain, a major city of the Abu Dhabi Emirate. Using an 
electronic laboratory database, a total of 2,280 patients 
with at least one laboratory record for serum prolactin 
were identified [Figure 1]. Of those identified, 1,315 
patients with normal prolactin levels (male range: 2.6– 
13.1 ng/mL, female range: 3–27 ng/mL) were excluded. 
Additionally, 458 patients were excluded due to incom- 
plete work-ups or insufficient documentation of their 
hyperprolactinaemia’s aetiology. The electronic medical 
records of the remaining patients were reviewed and 
demographic and clinical data were extracted. 
Hyperprolactinaemia was defined as a serum pro- 
lactin >13.1 ng/mL in males and >27 ng/mL in females. 
Only one type of prolactin assay (Beckman Dxl 800, 
Beckman Coulter Inc, Atlanta, Georgia, USA) was used 
in this study; this assay has superior specificity for mono- 
meric prolactin, therefore screening for macroprolactin 
excess was not routinely performed in the current cohort 
of patients. Prolactinomas were diagnosed based on elev- 
ated prolactin levels and evidence of pituitary adenomas 
from magnetic resonance imaging (MRI) scans.11 Pro- 
lactinomas were classified as macroprolactinomas (≥1 cm) 
or microprolactinomas (<1 cm) based on the size of the 
tumours. Prolactin levels <200 ng/mL (off-treatment) 
in patients with a sellar mass >1 cm were considered to 
be suggestive of the stalk effect.12 PCOS was accepted 
as the cause of hyperprolactinaemia if a diagnosis was 
documented by an experienced gynaecologist or endocri- 
nologist. Hypothyroidism was considered responsible 
for hyperprolactinaemia in the absence of other causes 
of hyperprolactinaemia, a simultaneous elevation of both 
thyroid stimulating hormones (TSH) and prolactin 
levels and restoration of normal prolactin level after 
normalisation of serum TSH. Patients were designated 
as having drug-induced hyperprolactinaemia if they were 
receiving medications recognised to elevate prolactin 
such as anti-emetics, antipsychotics, tricyclic antidepr- 
essants, serotonin re-uptake inhibitors and dopamine 
antagonists. Idiopathic hyperprolactinaemia was diagn- 
osed in patients with persistent hyperprolactinaemia 
and a negative pituitary MRI in the absence of other 
causes. Hyperprolactinaemia attributed to acute illness 
was diagnosed in patients with acute pain or infection, 
in those admitted to the intensive care unit and in the 
absence of any secondary cause of prolactin elevation. 
Transient hyperprolactinaemia was diagnosed in patients 
who had unexplained elevation of prolactin in a single 
reading that normalised spontaneously on repeat testing. 
Data were extracted using Microsoft Excel 2011 
(Microsoft Corp., Redmond, Washington, USA) and 
analysed in Stata SE, Version 15.1 (StataCorp LLC, 
College Station, Texas, USA). Qualitative variables were 
summarised using descriptive statistics. Results were 
 
Figure 1: Flow chart showing this study’s inclusion 
process of hyperprolactinaemic patients who underwent 
evaluation for serum prolactin level at Tawam Hospital, 
Al Ain, United Arab Emirates, between 2009 and 2015.
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presented as absolute and relative frequencies and 
quantitative variables as mean ± standard deviation or 
median with minimum and maximum as appropriate.
The study was approved by the Al Ain Medical 
District Human Research Ethics Committee (CRD 
471/16, AAMDHREC Protocol No. 16/58).
Results
A total of 507 patients with hyperprolactinaemia were 
included in this study. The mean age of patients at 
the time of prolactin evaluation was 36 ± 13.2 years. 
Most patients were female (67.1%) and UAE nationals 
(76%). The reason for ordering prolactin testing was 
available for 461 patients (90.9%). The test was most 
commonly used to evaluate menstrual disorders (29.5%), 
infertility (18%) and sellar masses (14.3%) and to rule 
out seizures (13.4%). In females, prolactin was requested 
most commonly to investigate menstrual disorders, 
infertility and hirsutism compared to excluding true 
seizures and evaluating sellar masses and infertility in 
males [Table 1]. 
The most common causes were prolactinomas 
(17%), transient hyperprolactinaemia (14.6%) and drug- 
induced hyperprolactinaemia (14.4%). Of the 86 patients 
with prolactinomas, 27 patients had macroprolacti- 
nomas. Of the 73 patients with transient hyperprolacti- 
naemia, 58 patients were females and 27 underwent 
prolactin measurement for evaluating infertility. Of the 
73 patients who were diagnosed with drug-induced 
hyperprolactinaemia, 22 were on antipsychotics, 15 
were on antimotility drugs, three were taking anti- 
depressants and one was on anti-epileptic monotherapy. 
Fewer patients (n = 32) were using multiple medications. 
The most frequently used monotherapy drugs were 
risperidone (41.5%), metoclopramide (19.5%) and dom- 
peridone (17.1%). In total, 60 patients (11.8%) were 
diagnosed with PCOS and seizures were present in 7.7% 
of cases. A small proportion of patients (6.7%) had been 
diagnosed with sellar masses other than prolactinomas. 
Microprolactinomas and transient hyperprolactinaemia 
were more frequently diagnosed in females compared 
with other sellar masses, seizures, CKD and acute 
illnesses, all of which were found to be related to 
hyperprolactinaemia in males [Table 2]. 
The highest median serum concentration of prolactin 
was 191 ng/mL (range: 14.6–2000 ng/mL) and was noted 
in patients with prolactinoma. For the other aetiologies, 
there was an overlap in the median prolactin level which 
was not predictive of aetiology. Patients with transient 
hyperprolactinaemia had a prolactin level ranging from 
13.4–77 ng/mL. Similarly, mild-to-moderate hyperpro- 
lactinaemia was seen in PCOS cases with only one patient 
having a prolactin level >85 ng/mL. Prolactin levels in 
Table 1: Common reasons for requesting serum prolactin 






Menstrual disorders 136 (43) - 136 (29.5)
Infertility 57 (18) 26 (17.9) 83 (18)
Work-up/follow-up 
on sellar masses
33 (10.4) 33 (22.8) 66 (14.3)
To exclude seizures 18 (5.7) 44 (30.3) 62 (13.4)
Screening while on 
psychiatric drugs
23 (7.3) 17 (11.7) 40 (8.7)
Hirsutism 31 (9.8) - 31 (6.7)
Galactorrhoea 24 (7.6) 3 (2.1) 27 (5.9)
Other‡ 30 (9.5) 14 (9.7) 44 (9.7)
Erectile dysfunction - 13 (9) 13 (2.8)
*Reasons for prolactin testing were unknown in 46 patients (25 females 
and 21 males).  †Percentages do not add up to 100 as patients may have 
had multiple reasons.  ‡Other reasons included headaches (n = 9), hypo- 
pituitarism (n = 7), lactation difficulties (n = 7), breast pain (n = 6), gyn- 
aecomastia (n = 5), delayed puberty (n = 3), testicular pain (n = 2), re- 
current miscarriages (n = 2), decreased libido (n = 2) and acne (n = 1).
Table 2: The aetiologies of hyperprolactinaemia in a sample 








Prolactinoma 63 (18.5) 23 (13.8) 86 (17)
Microprolactinoma 48 (14.1) 11 (6.6) 59 (11.6)
Macroprolactinoma 15 (4.4) 12 (7.2) 27 (5.3)
Transient 58 (17.1)  16 (9.6) 74 (14.6)
Drug-induced 48 (14.1) 25 (15) 73 (14.4)
PCOS 60 (17.6) - 60 (11.8)




12 (3.5) 22 (13.2) 34 (6.7)
Acute illness 11 (3.2) 23 (13.8) 34 (6.7)
Idiopathic 25 (7.4) 5 (3) 30 (5.9)
CKD 9 (2.6) 19 (11.4) 28 (5.5)
Pregnancy 20 (5.9) - 20 (3.9)
Other† 13 (3.8) 3 (1.8) 16 (3.2)
Empty sella syndrome 8 (2.4) 1 (0.6) 9 (1.8)
PCOS = polycystic ovarian syndrome; CKD = chronic kidney disease.
*Percentages do not add up to 100 as reported causes are not mutually 
exclusive.  †Other reasons included breastfeeding (n = 8), localised breast 
irritation/infection/surgery (n = 6), hypothyroidism (n = 4), hypoplastic 
pituitary (n = 1) and syncope (n = 1). 
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patients with drug-induced hyperprolactinaemia ranged 
from 19.6–240 ng/mL. Patients with other sellar masses 
had prolactin levels which ranged from 13–196 ng/mL; 
of which, 32 patients (94.1%) had levels <100 ng/mL 
and only two (5.9%) had levels >150 ng/mL. Overall, 
prolactin levels >250 ng/mL were only found in 14 
patients (2.8%). In two patients (14.2%), hyperprolac- 
tinaemia was due to pregnancy while in the remaining 
cases it was due to prolactinoma. Serum prolactin levels 
higher than 500 ng/mL were only seen in macroprolac- 
tinoma patients [Table 3].
Discussion 
This is the first study to comprehensively describe the 
aetiologies of hyperprolactinaemia in a large cohort of 
patients presenting to a tertiary referral center in UAE. 
Results showed that a significant proportion of patients 
were diagnosed with transient hyperprolactinaemia.
Hyperprolactinaemia negatively affects gonado- 
tropin releasing hormones and results in menstrual dis- 
orders and symptoms of hypogonadism.1 Hence, most 
patients in the current study were found to have under- 
gone prolactin evaluation because of menstrual disorders, 
infertility or erectile dysfunction. A large number of 
patients underwent prolactin evaluation to rule out a 
seizure disorder because prolactin has been shown to 
be elevated in patients with seizures.13 In fact, levels 
two times above the baseline obtained 10–20 minutes 
after seizure activity have been reported as suggestive 
of seizure diagnosis with 46.1–60% sensitivity and 96% 
specificity.14 However, patients with syncope may also 
experience mild prolactin elevation.14 Furthermore, 
a recent study of patients admitted to an epilepsy 
monitoring unit to distinguish psychogenic from 
epileptic seizures questioned the role of prolactin, with 
29% and 16% false positive and false negative rates, 
respectively.15 Therefore, physicians ordering prolactin 
level for assessing seizures or pseudo-seizures should 
be cognisant of the above limitations. Another reason 
for ordering prolactin testing was to evaluate sellar 
masses, which are relatively common with a prevalence 
of 0.1%.16 The distinction between prolactinomas and 
other sellar masses is an essential diagnostic step, as 
medical therapy is the treatment of choice for the former 
while surgery may be needed for the latter. Some of the 
current patients (7.8%) underwent prolactin testing to 
screen for hyperprolactinaemia while on psychotropic 
medications. This practice is in-line with the current 
guidelines advocating for hyperprolactinaemia screening 
in such patients because of the high prevalence (44%) 
of hyperprolactinaemia in this setting.17,18 
In the current study, prolactinoma was the most 
frequent cause of hyperprolactinaemia (17%). Previous 
studies have similarly shown that prolactinoma is the 
most common cause of hyperprolactinaemia but with 
much higher rates (25.6–56.6%).4,5 The lower rate in 
the current study could be attributed to the patients’ 
heterogeneity and the inclusion of prolactin testing for 
both inpatients and outpatients.
Data on the prevalence of transient hyperpro- 
lactinaemia is limited. In the current study, transient 
hyperprolactinaemia was the second most common 
aetiology of hyperprolactinaemia and was diagnosed 
mostly in women being evaluated for infertility. One 
study documented a transient rise of prolactin in 
females during their mid-cycle; the rate rises to 94% in 
those with infertility, ranging between 25–75 ng/mL 
and usually lasting 1–3 days.19 Additionally, prolactin 
follows a circadian rhythm with the highest reading 
occurring during sleep and immediately after awakening.12 
It also increases after sexual intercourse, following a 
protein-rich meal and during stress.12 Whyte et al. 
reported using antecubital fossa cannula to avoid stress, 
normalising prolactin levels in 17% of referred patients 
with hyperprolactinaemia with repeat testing only; this 
increased by 10% after a 120-minute rest period.20 
Moreover, prolactin levels ≥94 ng/mL had 97% specif- 
icity in identifying true hyperprolactinaemia.20 In keeping 
Table 3: Frequency and serum prolactin levels of endocrine 
and non-endocrine causes of hyperprolactinaemia (N = 507)
Cause of 
hyperprolactinaemia




Prolactinoma 86 (17) 191 (14.6–2000)
Sellar masses except 
prolactinoma
34 (6.7) 41.3 (13–196)
PCOS 60 (11.8) 42.2 (27–92.2)
Empty sella syndrome 9 (1.8) 48.4 (29.4–78)
Hypothyroidism 4 (0.8) 28.3 (13.4–38)
Non-endocrine
Transient 74 (14.6) 32.5 (13.4–77)
Drug-induced 73 (14.4) 68.4 (19.6–240)
Seizures 39 (7.7) 37.9 (13.6–221.2)
Acute illness 34 (6.7) 32.4 (14–70.2)
Idiopathic 30 (5.9) 47.7 (13.6–115)
CKD 28 (5.5) 50.1 (13.9–151.7)
Pregnancy 20 (3.9) 87.4 (24–490)
Other* 16 (3.2) 48.2 (18–167.8)
PCOS = polycystic ovarian syndrome; CKD = chronic kidney disease
*Other reasons included breastfeeding (n = 8), localised breast irritation/
infection/surgery (n = 6), hypoplastic pituitary (n = 1) and syncope (n = 1).
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with this finding, the current patients had prolactin 
levels ranging between 13.4–77 ng/mL. As knowledge 
of stress at the time of blood extraction or other 
physiological processes described earlier may not be 
readily available to the physician, assessment of serum 
prolactin levels should be repeated in patients with 
mild hyperprolactinaemia or in the absence of typical 
symptoms. This recommendation conflicts with the 
Endocrine Society Guidelines, which suggest that a 
single prolactin evaluation is enough to diagnose hyper- 
prolactinaemia. However, this recommendation supports 
other experts’ recommendations.7,20,21 Such an approach 
is expected to reduce both patient anxiety and unnec- 
essary pituitary imaging costs.
Drugs such as antipsychotics, antidepressants and 
anti-emetics may alter the neuroendocrine control 
mechanisms regulating prolactin secretion and cause 
modest prolactin elevation.8 Medications inducing 
hyperprolactinaemia constituted 14% of all cases in 
the current study, where most patients were on anti- 
psychotics or anti-emetics. Vilar et al. reported a similar 
rate (12%) in Brazil; however, the rate was much higher 
(45.9%) in Scotland with rising prevalence during 
the last years of the study.4,5 Recently, Alosaimi et al. 
reported a high prevalence of hyperprolactinaemia in 
psychiatric patients as well as guidelines that recommend 
screening for hyperprolactinaemia in such patients.18 
The current institution is not a referral centre for 
psychiatric patients and has no inpatient psychiatric 
services, which may contribute to this difference. Any 
treatment modifications in psychiatric patients such 
as switching to agents with no or only a minor effect 
on prolactin levels (e.g. bupropion, mirtazapine and 
aripiprazole) or even initiating dopamine agonist 
therapy should be done cautiously and in consultation 
with the treating psychiatrist to avoid exacerbating 
underlying psychiatric conditions.8,21
PCOS is a common disorder in young adults and 
contributes to 13–16% of all cases of hyperprolac- 
tinaemia.7 The rate in the current study is slightly 
lower (11.8%) as all cases of hyperprolactinemia were 
analysed without limiting the sample to outpatient 
cases as has been done in other studies. On the other 
hand, the rate in the current study might be over- 
estimated since Tawam Hospital is the largest and only 
governmental fertility centre in Al Ain. Moreover, no 
data are available on the number of PCOS patients who 
had pituitary MRIs; therefore, microprolactinomas may 
have been missed. However, the prolactin levels in those 
patients were moderate, ranging between 28–92 ng/mL 
and only one patient (1.7 %) had a prolactin level >85 
ng/mL. A recent study suggested that in patients with 
PCOS, a prolactin >85 ng/mL might indicate the pre- 
sence of adenomas with 77% sensitivity and 100% 
specificity.22
Sellar masses, excluding prolactinomas, could cause 
mild hyperprolactinaemia by inhibiting dopamine tran- 
sport on the hypothalamus-pituitary axis. In this study, 
6.7% of all cases of hyperprolactinaemia had other 
sellar masses with a median prolactin level of 33 ng/mL; 
the measured levels rarely rose above 100 ng/mL. Vilar 
et al. showed that a non-functioning adenoma contrib- 
uted to 6.6% of all hyperprolactinaemia cases with 82% 
of patients having prolactin levels <100 ng/mL.4 
Idiopathic hyperprolactinaemia has been reported 
as the cause of hyperprolactinaemia in 3.6–27.8% of 
all cases. This wide range reflects the differences found 
in the studied population and may be due to possible 
underestimation of macroprolactin or an incomplete 
work-up of patients.3–5 In the current study, 3.2% of 
patients were diagnosed with idiopathic hyperprolac- 
tinaemia; none had adenoma on a pituitary MRI scan.
Prolactin levels were shown to be predictive of 
macroprolactinoma in the current study as patients with 
macroprolactinomas had the highest prolactin levels. 
Except during pregnancy (n = 2), all other patients 
with prolactin levels >250 ng/mL were diagnosed with 
macroprolactinomas. Similarly, Vilar et al. found that 
only 4.2% of non-prolactinoma patients had prolactin 
levels >250 ng/mL and readings of >500 ng/mL were 
seen exclusively in patients with prolactinoma.4 Prolactin 
levels varied and were of no predictive value for other 
aetiologies. 
The current study had several strengths. It is the 
largest study assessing hyperprolactinaemia in the MENA 
region. Furthermore, real-world data have been reported 
on all inpatients and outpatients with hyperprolac- 
tinaemia, unlike many previous reports primarily focusing 
on patients encountered in outpatient clinics. Also, a 
single prolactin assay was used in this study. However, 
the study also has some limitations. As this was a 
single centre study, the results may not be generalisable 
to other clinical settings. Additionally, data were 
collected retrospectively. In total, 20% of the patients 
with hyperprolactinaemia were excluded because of an 
incomplete work-up. Also, macroprolactinaemia may 
have been underdiagnosed in the study as macropro- 
lactin is not screened routinely. Excessive evaluation 
of patients for hyperprolactinaemia could have been 
conducted by non-endocrinologists with limited knowl- 
edge of macroprolactin interference.
Conclusion
Prolactin testing is most commonly requested for eval- 
uation of menstrual disorders, infertility and sellar masses. 
As a sizable proportion of the current patients had 
transient hyperprolactinaemia, repeated prolactin meas- 
urement is recommended before further investigations 
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are considered. Prolactinomas and medications were 
the commonest causes of non-transient hyperprolac- 
tinaemia in the current study. A prolactin level >250 ng/mL 
was highly suggestive of macroprolactinoma.
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